Ignite Creation Date:
2025-12-24 @ 9:12 PM
Ignite Modification Date:
2026-01-04 @ 5:17 PM
Study NCT ID:
NCT02541604
Status:
TERMINATED
Last Update Posted:
2020-02-25
First Post:
2015-08-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-11-30
Start Date Type:
ACTUAL
Primary Completion Date:
2019-06-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-06-06
Completion Date Type:
ACTUAL
First Submit Date:
2015-08-18
First Submit QC Date:
None
Study First Post Date:
2015-09-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-11-11
Results First Submit QC Date:
None
Results First Post Date:
2020-02-25
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-02-24
Last Update Post Date:
2020-02-25
Last Update Post Date Type:
ACTUAL